Research & Development
Scientific Overview
Scientific Presentations
Scientists
Clinical Studies
Clinical Trial Participation
Clinical Trial Sites
Pre-Clinical
Research
Product Pipeline
Scientific Reports
 |
||||||||||
 |
 |
|||||||||
 |
 |
 |
 |
 |
||||||
 |
 |
|||||||||
 |
||||||||||
 |
||||||||||
 |
||||||||||
 |
||||||||||
 |
||||||||||
 |
FGF-1141: Treatment Applications | |||||||||
|
CVBT believes – and is studying whether – FGF-1141 can be applied to multiple tissues in the body that become injured due to a decreased blood flow. This injury, known as tissue ischemia, is most often caused by the blockage of arteries supplying blood to the tissue. CVBT’s current development efforts for FGF-1141 are grouped by the type of tissue that is proposed for treatment. Click on the image below to learn more about how FGF-1141 applies to various areas of the body.
Use of
this site constitutes agreement to our Terms and Conditions Some content on this site requires the free Adobe
Reader. | ||||||||||
 |
||||||||||
 |
|
|
|
|
|
|
|
|
|
|
12/11/2008
CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial
11/25/2008
CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
11/13/2008
CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate
9/9/2008
CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial